Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (April 2005)
23 slides from Resonance Health's investor presentation, April 2005
Slide 1: Commercialising the FerriScan Technology: The Future of Liver Diagnosis
Commercialising the FerriScan™ Technology “The Future of Liver Diagnosis” Investor Update April 2005 1
Slide 2: Commercialising the FerriScan Technology
Commercialising the FerriScan™ Technology “The Future of Liver Diagnosis” • Resonance Health Limited (ASX:RHT) – specialises in diagnostic imaging technology, focussing initially on the liver. • The FerriScan™ Technology is a novel, non-invasive liver diagnostic with global applications developed by
Slide 3: What is the FerriScan Technology
What is the FerriScan™ Technology • A safe, non-invasive and accurate test to measure liver iron concentration • Utilises existing MRI equipment, proprietary software and a patented iron “marker” known as “R2” • Provides clinicians around the world with a new and safe diagnostic tool to track liver
Slide 4: Why Test for Iron Overload?
Why Test for Iron Overload? • Chronic disorders of iron metabolism are among the most common genetic diseases (1 in 200 for HHC) • The result is too much iron is absorbed by the digestive system and accumulates in the body (and in its largest organ – the liver) • Iron overload has previously been di
Slide 5: Diseases Associated With Iron Overload
Diseases Associated With Iron Overload • Haemochromatosis – A hereditary disease in which excessive amounts of iron are absorbed and stored in the body, particularly the liver. Treatment is typically blood removal every week over a two year period. Hereditary Haemochromatosis (HHC) is the most commo
Slide 6: Distribution Map – Iron Overload Disorders
Distribution Map – Iron Overload Disorders 4,000,000 10,000,000 100,000 6
Slide 7: Other Direct Applications for the FerriScan Technology Platform
Other Direct Applications for the FerriScan™ Technology Platform • Hepatitis C – Assessment of liver iron levels to ensure the efficacy of prescribed drug treatments (1 in 100 people in developed countries) • Adjunct to blood tests in the diagnosis of Hereditary Haemochromatosis (HHC) or to rule out
Slide 8: Liver Biopsy is the Current Gold Standard for Measuring Liver Iron
Liver Biopsy is the Current “Gold Standard” for Measuring Liver Iron If an effective alternative were available, would patients choose needle biopsy? 8
Slide 9: FerriScan Has The Potential To Reduce Cost & Improve Patient Care
FerriScan™ Has The Potential To Reduce Cost & Improve Patient Care # $ % &'( $ ) ! * $ % + $ ) , - " .% ''' - .'%''' 9
Slide 10: The FerriScan Test Process Leverages Existing MRI Infrastructure
The FerriScan™ Test Process Leverages Existing MRI Infrastructure •Utilizes existing MRI scanners with no new equipment purchases •MRI Images processed off-line at a central centre, using IVB proprietary software, optimising quality control and security of the technology •Provides a clear, unambiguo
Slide 11: FerriScan offers significant benefits over the gold standard alternative
FerriScan™ offers significant benefits over the “gold standard” alternative for iron level tests FerriScan™ Liver Needle Biopsy 1. Non-invasive and painless 1. Invasive, painful and a potential 2. Can be performed regularly if health risk from bleeding necessary 2. Can only be performed about 3. No
Slide 12: Available Globally – Processed Locally
Available Globally – Processed Locally • MRI units can be enabled remotely to incorporate the IVB Technology and to perform the FerriScan™ Test • Liver Scans from the MRI (off-line) are sent via the Internet to the FerriScan™ Analysis Service Centre in Perth, Western Australia • FerriScan’s propriet
Slide 13: USA & Australian Market Potential
FerriScan™ / Iron Overload Application USA & Australian Market Potential Australia USA Total Market: genetic 125,000 2,000,000 predisposition for iron overload Addressable Market: Clinically 33,000 750,000 significant iron overload Potential FerriScan™ service fee $250 - $350 $250 - $450 (AUD)* Addr
Slide 14: Growth in Current Diagnostic Tests for Iron Overload
Growth in Current Diagnostic Tests for Iron Overload 2,000,000 1,401,005 1,500,000 1,041,971 1,250,347 Over a five year consecutive 877,048 1,000,000 731,138 period (1999-2003) financial 500,000 years), the volume of blood 0 iron studies performed 1998/99 1999/00 2000/01 2001/02 2002/03 increased by
Slide 15: FerriScan Indicative Model of Potential Gross Profit
FerriScan™ Indicative Model of Potential Gross Profit Based on %US / Aus Potential Revenue 1 Potential Test Numbers Addressable Gross Profit @ Market 65% GM 20,000 2.5% $6M $3.9M 40,000 5% $12M $7.8M 60,000 7.5% $18M $11.7M 100,000 2 12.5% $30M $19.5M Note: 1 At average revenue of AUD$300 per test 2
Slide 16: FerriScan unites strong margins, short-time to market and a novel diagnostic service
FerriScan unites strong margins, short-time to market and a novel diagnostic service 5 7 1 0 1 6 1 3 1 3 4 3 " 0 4 0 2 3 / 5 0 45 4 " 1 4 / 3 4 5 6 3 5" + 7 , 3 0 0 3 / 16
Slide 17: Benchmark examples of Diagnostic Imaging companies
Benchmark examples of Diagnostic Imaging companies 0 1 0 1 Company Description Mkt Cap: Cash: Status MedicSight Medicsight is a medical imaging software company. Its core MC: US$165m FDA approvals for three products (USA) technology is focused on developing automatic detection and Cash: US$8m Nov200
Slide 18: Board of Directors – Resonance Health
Board of Directors – Resonance Health • Hon. Dr Michael Wooldridge (Non-Executive Chairman) – Former Australian Federal Minister for Health • Mr Tony Fitzgerald (Executive Director) – Legal and healthcare licensing expertise, 18 years experience in commercialising healthcare and biotech projects – C
Slide 19: New Operational Management
New Operational Management • Dr James Williams BSc (Hons) PhD MBA, CEO (appointed May 2004) – Prior roles include CEO, implantable medical device product with regulatory approvals in Europe, US, Australia in under 2 years, successful surgeon accreditation program and reimbursement program. – Co-foun
Slide 20: RHT Pro-forma capital structure
RHT Pro-form capital structure Assumes 100% ownership of IVB (As at 31 March 2005) Shares on issue: Currently on issue and listed (RHT) 111,353,585 Proposed issue of ordinary shares to IVB shareholders 68,140,438 Outstanding performance shares 13,000,000 Total shares on issue – all classes 192,494,0
Slide 21: Major Progress Towards Commercialisation of FerriScan
Major Progress Towards Commercialisation of FerriScan™ 1. TGA listing achieved in Australia – December 2004 2. European marketing approval – CE Mark achieved, January 2005 3. US FDA 510(k) clearance received January 2005 4. DCA Group (Australia’s largest diagnostic imaging group) confirmed as partne
Slide 22: Forward looking statements and risks
Forward looking statements and risks This presentation contains forward-looking statements that are based on management’s current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the healthcare techn
Slide 23: Contact Details
Contact Details Tony Fitzgerald, Executive Director Resonance Health Ltd ABN 96 006 762 492 Ground Floor, 117 Stirling Highway, NEDLANDS Western Australia 6009 Tel +61 8 9389 5933 Fax +61 8 9389 5944 www.resonancehealth.com James Williams, CEO Inner Vision Biometrics Pty Ltd ABN 11 092 813 244 First
Resonance Health — Investor Presentation (April 2005) on 6ix